Alexander Streuer

Mannheim, BW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Dose-Adjusted Treatment With 7-Day Venetoclax Plus Azacitidine or Decitabine in Patients With Acute Myeloid Leukaemia.

Dose-Adjusted Treatment With 7-Day Venetoclax Plus Azacitidine or Decitabine in Patients With Acute Myeloid Leukaemia.

Journal: European journal of haematology

Published: May 26, 2026

Dynamic Mortality Risk Prediction in Myelodysplastic Syndromes Using Longitudinal Clinical Data.

Dynamic Mortality Risk Prediction in Myelodysplastic Syndromes Using Longitudinal Clinical Data.

Journal: JCO clinical cancer informatics

Published: December 23, 2025

Clinical benefit of additional whole-exome sequencing over panel sequencing in an all-comer real-world molecular tumor board.

Clinical benefit of additional whole-exome sequencing over panel sequencing in an all-comer real-world molecular tumor board.

Journal: ESMO open

Published: July 08, 2025

Primary CD34+ cells of patients with vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome are highly sensitive to targeted treatment with TAK-243.

Primary CD34+ cells of patients with vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome are highly sensitive to targeted treatment with TAK-243.

Journal: British journal of haematology

Published: June 17, 2025

Gilteritinib in an Isolated CNS Recurrence of FLT3-ITD Positive AML.

Gilteritinib in an Isolated CNS Recurrence of FLT3-ITD Positive AML.

Journal: Clinical case reports

Published: April 21, 2025

Targeting tumoral heterogeneity in lung cancer: a novel, CT-texture-guided targeted biopsy approach with exome sequencing.

Targeting tumoral heterogeneity in lung cancer: a novel, CT-texture-guided targeted biopsy approach with exome sequencing.

Journal: NPJ precision oncology

Published: April 02, 2025

Inter-modality variance of blast quantification in patients with myelodysplastic neoplasms (MDS) and its impact on risk stratification and overall survival.

Inter-modality variance of blast quantification in patients with myelodysplastic neoplasms (MDS) and its impact on risk stratification and overall survival.

Journal: Leukemia research

Published: February 27, 2025

Machine learning-based in-silico analysis identifies signatures of lysyl oxidases for prognostic and therapeutic response prediction in cancer.

Machine learning-based in-silico analysis identifies signatures of lysyl oxidases for prognostic and therapeutic response prediction in cancer.

Journal: Cell communication and signaling : CCS

Published: September 25, 2024

The bispecific innate cell engager AFM28 eliminates CD123+ leukemic stem and progenitor cells in AML and MDS.

The bispecific innate cell engager AFM28 eliminates CD123+ leukemic stem and progenitor cells in AML and MDS.

Journal: Nature communications

Published: February 21, 2024

Treatment with the apoptosis inhibitor Asunercept reduces clone sizes in patients with lower risk Myelodysplastic Neoplasms.

Treatment with the apoptosis inhibitor Asunercept reduces clone sizes in patients with lower risk Myelodysplastic Neoplasms.

Journal: Annals of hematology

Published: December 19, 2023

Instructive interaction between myelodysplastic hematopoiesis and the bone marrow microenvironment at the single-cell level.

Instructive interaction between myelodysplastic hematopoiesis and the bone marrow microenvironment at the single-cell level.

Journal: Blood neoplasia

Published: December 13, 2023

ASXL1 mutations are associated with a response to alvocidib and 5-azacytidine combination in myelodysplastic neoplasms.

ASXL1 mutations are associated with a response to alvocidib and 5-azacytidine combination in myelodysplastic neoplasms.

Journal: Haematologica

Published: February 09, 2023

Showing 1-12 of 21

Last Updated: 09/26/2026